Literature DB >> 24289305

Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase.

Kathleen M Frey1, William T Gray, Krasimir A Spasov, Mariela Bollini, Ricardo Gallardo-Macias, William L Jorgensen, Karen S Anderson.   

Abstract

Using a computationally driven approach, a class of inhibitors with picomolar potency known as the catechol diethers were developed targeting the non-nucleoside-binding pocket of HIV-1 reverse transcriptase. Computational studies suggested that halogen-bonding interactions between the C5 substituent of the inhibitor and backbone carbonyl of conserved residue Pro95 might be important. While the recently reported crystal structures of the reverse transcriptase complexes confirmed the interactions with the non-nucleoside-binding pocket, they revealed the lack of a halogen-bonding interaction with Pro95. To understand the effects of substituents at the C5 position, we determined additional crystal structures with 5-Br and 5-H derivatives. Using comparative structural analysis, we identified several conformations of the ethoxy uracil dependent on the strength of a van der Waals interaction with the Cγ of Pro95 and the C5 substitution. The 5-Cl and 5-F derivatives position the ethoxy uracil to make more hydrogen bonds, whereas the larger 5-Br and smaller 5-H position the ethoxy uracil to make fewer hydrogen bonds. EC50 values correlate with the trends observed in the crystal structures. The influence of C5 substitutions on the ethoxy uracil conformation may have strategic value, as future derivatives can possibly be modulated to gain additional hydrogen-bonding interactions with resistant variants of reverse transcriptase.
© 2013 John Wiley & Sons A/S.

Entities:  

Keywords:  HIV-1 reverse transcriptase; halogen bonds; non-nucleoside reverse transcriptase inhibitors; structure-activity relationships; structure-based drug design

Mesh:

Substances:

Year:  2014        PMID: 24289305      PMCID: PMC3999282          DOI: 10.1111/cbdd.12266

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  27 in total

1.  Mutations in the primer grip region of HIV reverse transcriptase can increase replication fidelity.

Authors:  M Wisniewski; C Palaniappan; Z Fu; S F Le Grice; P Fay; R A Bambara
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

2.  Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.

Authors:  Daniel M Himmel; Kalyan Das; Arthur D Clark; Stephen H Hughes; Abdellah Benjahad; Said Oumouch; Jérôme Guillemont; Sophie Coupa; Alain Poncelet; Imre Csoka; Christophe Meyer; Koen Andries; Chi Hung Nguyen; David S Grierson; Eddy Arnold
Journal:  J Med Chem       Date:  2005-12-01       Impact factor: 7.446

Review 3.  Anti-human immunodeficiency virus drug combination strategies.

Authors:  A M Vandamme; K Van Vaerenbergh; E De Clercq
Journal:  Antivir Chem Chemother       Date:  1998-05

4.  Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design.

Authors:  Eric B Lansdon; Katherine M Brendza; Magdeleine Hung; Ruth Wang; Susmith Mukund; Debi Jin; Gabriel Birkus; Nilima Kutty; Xiaohong Liu
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

5.  The accuracy of reverse transcriptase from HIV-1.

Authors:  J D Roberts; K Bebenek; T A Kunkel
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

6.  The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.

Authors:  Joeri Auwerx; Joke Van Nieuwenhove; Fátima Rodríguez-Barrios; Sonia de Castro; Sonsoles Velázquez; Francesca Ceccherini-Silberstein; Erik De Clercq; María-José Camarasa; Carlo-Federico Perno; Federico Gago; Jan Balzarini
Journal:  FEBS Lett       Date:  2005-04-25       Impact factor: 4.124

7.  High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.

Authors:  Francesca Ceccherini-Silberstein; Federico Gago; Maria Santoro; Caterina Gori; Valentina Svicher; Fátima Rodríguez-Barrios; Roberta d'Arrigo; Massimo Ciccozzi; Ada Bertoli; Antonella d'Arminio Monforte; Jan Balzarini; Andrea Antinori; Carlo-Federico Perno
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

Authors:  Kalyan Das; Arthur D Clark; Paul J Lewi; Jan Heeres; Marc R De Jonge; Lucien M H Koymans; H Maarten Vinkers; Frederik Daeyaert; Donald W Ludovici; Michael J Kukla; Bart De Corte; Robert W Kavash; Chih Y Ho; Hong Ye; Mark A Lichtenstein; Koen Andries; Rudi Pauwels; Marie-Pierre De Béthune; Paul L Boyer; Patrick Clark; Stephen H Hughes; Paul A J Janssen; Eddy Arnold
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  8 in total

1.  From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection.

Authors:  Shalley N Kudalkar; Jagadish Beloor; Elias Quijano; Krasimir A Spasov; Won-Gil Lee; José A Cisneros; W Mark Saltzman; Priti Kumar; William L Jorgensen; Karen S Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-26       Impact factor: 11.205

2.  Computer-aided discovery of anti-HIV agents.

Authors:  William L Jorgensen
Journal:  Bioorg Med Chem       Date:  2016-07-21       Impact factor: 3.641

3.  Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.

Authors:  Won-Gil Lee; Kathleen M Frey; Ricardo Gallardo-Macias; Krasimir A Spasov; Mariela Bollini; Karen S Anderson; William L Jorgensen
Journal:  ACS Med Chem Lett       Date:  2014-10-13       Impact factor: 4.345

4.  Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.

Authors:  Tomoaki Sasaki; Zachary T K Gannam; Shalley N Kudalkar; Kathleen M Frey; Won-Gil Lee; Krasimir A Spasov; William L Jorgensen; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2019-06-26       Impact factor: 2.823

5.  Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV.

Authors:  Shalley N Kudalkar; Irfan Ullah; Nicole Bertoletti; Hanna K Mandl; José A Cisneros; Jagadish Beloor; Albert H Chan; Elias Quijano; W Mark Saltzman; William L Jorgensen; Priti Kumar; Karen S Anderson
Journal:  Antiviral Res       Date:  2019-04-26       Impact factor: 5.970

6.  Design, Conformation, and Crystallography of 2-Naphthyl Phenyl Ethers as Potent Anti-HIV Agents.

Authors:  Won-Gil Lee; Albert H Chan; Krasimir A Spasov; Karen S Anderson; William L Jorgensen
Journal:  ACS Med Chem Lett       Date:  2016-10-31       Impact factor: 4.345

7.  Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection.

Authors:  Shalley N Kudalkar; Jagadish Beloor; Albert H Chan; Won-Gil Lee; William L Jorgensen; Priti Kumar; Karen S Anderson
Journal:  Mol Pharmacol       Date:  2017-02-06       Impact factor: 4.436

8.  Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.

Authors:  Kathleen M Frey; David E Puleo; Krasimir A Spasov; Mariella Bollini; William L Jorgensen; Karen S Anderson
Journal:  J Med Chem       Date:  2015-03-05       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.